collaborators in Professor David Lane’s laboratory have shown that Phylogica’s FPPs are able to enhance the delivery of their peptides more effectively than other CPP approaches they’ve tried.
Last July, Singapore's Agency for Science, Technology and Research (A*STAR) and Prof. Sir David Lane, who is Chief Scientist of A*STAR and Director of the p53 Lab, formed a two year collaboration with Merck aimed at improving cellular delivery of macrocyclic peptides.
The advantage of macrocyclics over traditional classes of therapeutics is their ability to disrupt intracellular protein-protein disease interactions; the disadvantage is that they are too large to enter cells. The A*STAR/ p53Lab/Merck collaboration aims to "uncover the chemical and biophysical properties that influence peptide penetration into cells, as well as to explore the use of smart delivery systems that leverage natural cell entry mechanisms".
Dr. Rich Tillyer, Senior VP, Chemistry, Merck, said of the collaboration, "We believe that by combining expertise with A*STAR, we will make significant advances in our ability to apply peptide therapeutics to highly validated intracellular targets that have historically been out of reach. In that regard, this collaboration represents an important step towards novel medicines that will save and improve lives."
In 2015, Merck signed a multi-target discovery and optimization collaboration agreement with Peptidream aimed at generating macrocylic/constrained peptides against multiple targets of interest selected by Merck.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)